Kairos Pharma, LTD.

KAPA NYSE SEC CIK 1962011
Follow Kairos Pharma, LTD. Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$2M −41.9% vs same quarter last year
EPS, diluted −$0.59 −22.9% vs same quarter last year
Operating cash flow −$979K −16.8% vs same quarter last year
Operating income −$2M −40% vs same quarter last year
Net income by quarter
−$980K
−$1.3M
−$1.4M
−$1.4M
−$1.4M
−$1.7M
−$1.4M
−$2M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income4 fiscal years
−$6M−$4M−$2M$0FY22FY23FY24FY25
Show the numbers
YearNet income
FY25−$5.4M
FY24−$2.6M
FY23−$1.8M
FY22-